Clinical research
Panzyga® has demonstrated clinical efficacy and tolerability in PID, ITP and CIDP as part of our clinical development program. Explore the clinical evidence supporting the use of panzyga®.
About panzyga®
Panzyga® is the result of 40 years of fractionation experience at Octapharma and our continued commitment to patients and healthcare professionals.
Panzyga® approved indications
Panzyga® is used across a wide range of clinical indications, offering proven experience and support to healthcare professionals, patients and caregivers.
Replacement therapy in adults, and children and adolescents (0-18 years) in:1
Primary immunodeficiency syndromes (PID) with impaired antibody production.
Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum immunoglobulin (Ig) G level of <4g/l.
Immunomodulation in adults, and children and adolescents (0-18 years) in:1
Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count
Guillain Barré syndrome (GBS)
Kawasaki disease (in conjunction with acetylsalicylic acid)
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Multifocal motor neuropathy (MMN)
Manufacturing of panzyga®
Panzyga® leverages a state-of-the-art manufacturing process that delivers confidence for healthcare professionals, patients and caregivers.1-3
When medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.1
From donor to patient
Our production process explained in a short video
References
* PSAF=failure to mount at least a 2-fold rise in immunoglobulin G antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccines.
Panzyga® Summary of Product Characteristics.
Mersich C, et al. Biologicals 2017;45:33–38;
Radomski KU, et al. BioDrugs 2017;31:125–134.
This is an international website for Panzyga® and is intended for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC).
If you wish to contact Octapharma please use the contact form on our corporate website www.octapharma.com.
